Morbidity and mortality reduction associated with the use of erythropoietin

Nephron

Volumn 85, Issue SUPPL. 1, 2000, Pages 2-8

  Tsakiris, Dimitrios ^a  

^a GENERAL HOSPITAL OF VERIA   (Greece)

Author keywords

Anaemia; Cardiovascular disease; Dialysis; End stage renal disease; Erythropoietin; Risk reductions

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; EXERCISE; HUMAN; META ANALYSIS; METHODOLOGY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 0034027195     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045703     Document Type: Conference Paper

References (29)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998:32:S112-S119.
2. United States Renal Data System: Annual Data Report V. Patient mortality and survival. Am J Kidney Dis 1998;32(suppl 1):S69-S80.
3. Raine AEG, Margreiter R, Brunner FP, Ehrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tulveson G, Valderrábano F: Report on management of renal failure in Europe XII. Nephrol Dial Transplant 1992; 7(suppl 2):7-35.
4. Delano BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989: 14(suppl 1):14-18.
5. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999:10:1606-1615.
6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: The outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11: 1277-1285.
7. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safer ME, London GM: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-574.
8. Brenner RM, Wrone EM: The epidemic of cardiovascular disease in end-stage renal disease. Curr Opin Nephrol Hypertens 1999;8:927-932.
9. London GM, Marchais SJ, Guerin AP, Fabiani F, Motivier F: Cardiovascular function in haemodialysis patients. Adv Nephrol Necker Hosp 1991;20:249-273.
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
11. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998:13:1642-1644.
12. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
13. Madore F, Lowerie E, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997:8: 1921-1929.
14. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anaemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32(suppl 4):S133-S141.
15. Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62: 161-165.
16. Dunn CJ, Markham A: Epoetin beta: A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 1996:2:299-318.
17. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KAA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489-493.
18. Evans RW, Radar B, Manninen DL: The quality of life of haemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263:825-830.
19. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300:573-578.
20. Revicki DA, Brown E, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-554.
21. Boran M, Dalva I, Yazieioglu A, Akbay E, Cetin S: Correction of anaemia in haemodialysis patients with recombinant human erythropoietin. Int Urol Nephrol 1993;25:197-203.
22. Moreno F, Lopez Gomez JM, Sanz-Guajardo D, Jofre R, Valderrábano F: Quality of life in dialysis patients. A Spanish multicentre study. Nephrol Dial Transplant 1996:11(suppl 2): 125-129.
23. Möcks J, Franke W, Ehmer B, Quarder O, Scigalla P: Analysis of safety database for long-term epoetin beta treatment: A meta analysis covering 3697 patients; in Koch KM, Stein G (eds): Pathogeneic and Therapeutic Aspects of Chronic Renal Failure. New York, Dekker, 1997, pp 163-179.
24. Becher H, Berthoux F, Briggs D, Escrig C, Gellert R, Jones E, Möcks J, Tsakiris D: Effect of EPO therapy on mortality in hemodialysis. Preliminary results from an EDTA Registry Study. XVth Int Congr Nephrol. Buenos Aires, May 2-6 1999.
25. Geerlings W, Morris RW, Brunner FP, Brynger H, Ehrich JH, Fassbinder W, Rizzoni G, Selwood NH, Tufveson G, Wing AJ: Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplant 1993:8:585-589.
26. National Kidney Foundation: Clinical practice guidelines for the treatment of anaemia of chronic renal failure: Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997;4(suppl 3): S192-S240.
27. Cameron JS: European best practice guidelines for the management of anaemia in patients with chronic renal anaemia. Nephrol Dial Transplant 1999;14(suppl 2):61-65.
28. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339: 584-590.
29. Macdougall IC, Ritz E: The normal haematocrit trial in dialysis patients with cardiac disease: Are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13:3030-3033.